Cancer Immunotherapy: CAR T as 'Car Race'

GEN Sounds of Science March 9, 2017Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies. How significant a setback is Juno Therapeutics’ halting development of JCAR015? How could some second-tier companies yet come out on top in the “car race”? Hosted on Acast. See acast.com/privacy for more information.